NeoGenomics is expected to report Q2 2026 revenue of approximately $196.99 million and a consensus loss of $0.06 per share, with the current stock price of $13.89 trading below the average analyst target of $15.67.
The primary story for this quarter is the commercial traction and market penetration of the recently launched RaDaR ST minimal residual disease (MRD) assay.
Investors are encouraged by the resolution of previous legal overhangs, including the settlement of federal healthcare fraud allegations, and the company's strategic pivot toward high-growth molecular testing. Strong performance in next-generation sequencing (NGS), which has consistently outpaced the core clinical business with double-digit growth, remains the critical driver for achieving long-term profitability.